Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
The Zhitong Finance App learned that Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
According to the news, Genting Xinyao's partner Calliditas announced several positive results from the 2024 International Society of Nephrology (ISN) World Nephrology Conference (WCN 2024). These significant long-term clinical benefits further prove that “Tolifukan” has a therapeutic effect in altering the course of IgA nephropathy disease.
According to reports, Nifukang has now been approved in mainland China, Macau, and Singapore in the Genting Xinyao Asia Equity Zone, and is expected to be commercialized in mainland China as early as May. According to Western Securities, 2024 is the year of the company's commercial transformation. Eiga and Nifukang are expected to accelerate their expansion, and several other catalysts will soon be launched, and the company's commercial product matrix is expected to be further enriched.